Cigna · Forteo · US health-plan appeal rights

Forteo denied as not FDA-approved for this use by Cigna?

Q: How long do I have to appeal a Cigna Forteo denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

Cigna's specific coverage criteria for forteo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Cigna / Express Scripts the applicable coverage policy — Anabolic Osteoporosis Agents (Forteo / Tymlos)

The Cigna angle on Forteo

## Why Cigna Denied Forteo as Not FDA-Approved

A "not FDA-approved" denial for teriparatide (Forteo) almost always reflects one of two issues: (1) a billing or coding error where the claim was submitted under a diagnosis code or indication that does not match teriparatide's FDA-approved labeling, or (2) Cigna's system incorrectly flagged the drug or indication. Teriparatide has FDA approval for specific osteoporosis indications — if your use falls within those, the denial is factually incorrect.

This type of denial is very often resolved at the internal appeal stage once the correct documentation is submitted.

## Federal Appeal Framework

Internal appeal: File immediately — the denial letter will state your deadline. Cigna must decide within 30 days for non-urgent requests. Attach the FDA prescribing label directly to the appeal letter.
External review (ACA §2719 / ERISA §503): If the internal appeal is denied, request independent external review within approximately 4 months. An independent clinical expert reviews the FDA approval status question without deference to Cigna's initial determination. Expedited review (72-hour turnaround) is available when delay poses a serious health risk.

## Documentation to Gather

1. FDA prescribing label: Download the current Prescribing Information (PI) for teriparatide from the FDA's Drugs@FDA database. Highlight the approved indication(s) that match your diagnosis. 2. Diagnosis confirmation: Physician notes and DXA scan confirming the diagnosis and its alignment with the FDA-approved indication. 3. Claim and coding review: Ask your prescriber's billing office to confirm that the diagnosis code (ICD-10) and procedure or drug code submitted on the claim accurately match the FDA-approved indication. A coding correction may resolve the denial without a formal appeal. 4. Prescriber letter: A brief letter from the treating physician confirming the on-label use, citing the specific FDA-approved indication, and attaching the relevant section of the prescribing label.

## Criteria-Mapping Structure

Obtain the exact language from Cigna's denial citing the not-FDA-approved basis. Compare it against the FDA prescribing label's approved indications section. Prepare a side-by-side document showing (a) Cigna's stated basis for the denial, (b) the FDA label language, and (c) your physician's documented diagnosis. This structure gives the internal reviewer everything needed to reverse the denial in a single review.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other denial reasons for Cigna Forteo

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.